RT Journal Article
SR Electronic
T1 A Single-Cell Tumor Immune Atlas for Precision Oncology
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.10.26.354829
DO 10.1101/2020.10.26.354829
A1 Paula Nieto
A1 Marc Elosua-Bayes
A1 Juan L. Trincado
A1 Domenica Marchese
A1 Ramon Massoni-Badosa
A1 Maria Salvany
A1 Ana Henriques
A1 Elisabetta Mereu
A1 Catia Moutinho
A1 Sara Ruiz
A1 Patricia Lorden
A1 Vanessa T. Chin
A1 Dominik Kaczorowski
A1 Chia-Ling Chan
A1 Richard Gallagher
A1 Angela Chou
A1 Ester Planas-Rigol
A1 Carlota Rubio-Perez
A1 Ivo Gut
A1 Josep M. Piulats
A1 Joan Seoane
A1 Joseph E. Powell
A1 Eduard Batlle
A1 Holger Heyn
YR 2020
UL http://biorxiv.org/content/early/2020/10/26/2020.10.26.354829.abstract
AB The tumor immune microenvironment is a main contributor to cancer progression and a promising therapeutic target for oncology. However, immune microenvironments vary profoundly between patients and biomarkers for prognosis and treatment response lack precision. A comprehensive compendium of tumor immune cells is required to pinpoint predictive cellular states and their spatial localization. We generated a single-cell tumor immune atlas, jointly analyzing >500,000 cells from 217 patients and 13 cancer types, providing the basis for a patient stratification based on immune cell compositions. Projecting immune cells from external tumors onto the atlas facilitated an automated cell annotation system for a harmonized interpretation. To enable in situ mapping of immune populations for digital pathology, we applied SPOTlight, combining single-cell and spatial transcriptomics data and identifying striking spatial immune cell patterns in tumor sections. We expect the tumor immune cell atlas, together with our versatile toolbox for precision oncology, to advance currently applied stratification approaches for prognosis and immuno-therapy.Competing Interest StatementJS is co-founder of Mosaic Biomedicals, Board member of Northern-Mosaic partnership and has ownership interests from Mosaic Biomedicals and Northern Biologics. JS received grant/research support from Mosaic Biomedicals, Northern Biologics, Roche/Glycart and Hoffmann la Roche. JS reports scientific consultancy role for Merck Serono, GSK, Eli Lilly. All authors declare no conflicts of interest associated with this manuscript. All other authors declare no conflicts of interest associated with this manuscript.